Autobahn Therapeutics is a San Diego-based biotechnology company dedicated to improving the lives of individuals affected by central nervous system (CNS) disorders. Their mission is to harness the regenerative power of the human body to develop innovative therapies that restore hope for those suffering from both rare and prevalent CNS diseases. By focusing on the brain and creating next-generation regenerative medicines, Autobahn Therapeutics aims to address the progressive and debilitating nature of these conditions, enabling individuals to live the futures they deserve.
With a brain-targeting chemistry platform and a high-confidence pipeline, Autobahn Therapeutics utilizes biomarker-driven development strategies to demonstrate on-target on-tissue activity and proof-of-mechanism early in the clinic. Their world-class team, comprising experts in thyromimetics, drug discovery and development, clinical operations, corporate development, and commercialization, is united by a common goal of restoring hope for people affected by CNS disorders. Through their validated human biology approach, Autobahn Therapeutics aims to create orally administered small molecule prodrugs with tailored distribution profiles that match disease pathophysiology, ultimately improving the health and well-being of individuals impacted by CNS disorders.
Generated from the website